(VCBeat) July. 30, 2021 -- THOTH (Suzhou) Medical Technology Co., Ltd. ("THOTH"), a leader in the medical sensor industry, recently completed a Series C financing of hundreds of millions, led by Orchid Asia Group and China Merchant Bank International Capital Management, with participation from China Growth Capital, Sinopharm Capital, Oriental Fortune Capital and Hangzhou Financial Investment. The existing investors Envision Capital and Dark Horse Ventures also increased their investments. Potential Capital served as the exclusive financial advisor.

Gao Linming, founder of THOTH, said, "This round of financing will be used in three aspects. First, to expand the marketing service team and market channels, and improve the 'customer success as the core' service system; Second, to strengthen the research and development from single-disease to multi-sign data products; Third, to build the upstream industrial chain and increase investment in basic research such as chips and new materials."

THOTH was founded in January 2016 and is headquartered in Suzhou Industrial Park. The company focuses on the research and development of flexible wearable medical devices and the application of medical big data artificial intelligence technology, is a high-tech enterprise in Jiangsu Province, which integrates research, production and marketing.

THOTH has innovatively designed disposable sensors that are similar to a "Band-Aid", integrating product and service value into the sensor so that users pay only for the Band-Aid and do not need to purchase medical equipment or medical systems. THOTH is focused on providing accurate, efficient, comfortable and safe clinical-level healthcare services to every user and is committed to creating a new healthcare ecosystem.

The 7 products developed by THOTH have obtained NMPA medical device product registration certificate and 30 patents. Their products cover dynamic ECG monitoring, continuous body temperature monitoring and fetal ECG monitoring, among which the core product "Wearable ECG Sensor" is the first wearable ECG sensor to obtain NMPA medical device product registration certificate, which has been used by 500,000 patients in more than 700 hospitals in 20 provinces and cities, and is unanimously recognized by hospitals and users.

Orchid Asia Group is an investment group with offices in Hong Kong, Shanghai, Beijing and Guangzhou. They focus on backing experienced executives in building franchises in Asia, with an emphasis in China. The company seeks to invest in expanding domestic enterprises in high barrier to entry businesses that have good growth prospects in the consumer services and products sector, as well as the outsourced manufacturing and services sector.

CGC is a China-focused seed and early venture investor since 2006. We back extraordinary entrepreneurs from seed to early growth in the enterprise, frontier tech, life science, marketplace, and consumer verticals. They pioneered fintech and enterprise innovations in China since founding in 2006 with a unique portfolio of fintech, enterprise software, frontier technology and marketplace players.